Risk factors for lower respiratory tract disease and outcomes in allogeneic hematopoietic stem cell transplantation recipients with influenza virus infection. Issue 9 (September 2022)

• Record Type: Journal Article
• Authors: Shiraiwa, Sawako; Harada, Kaito; Onizuka, Makoto; Kawakami, Shohei; Hara, Ryujiro; Aoyama, Yasuyuki; Amaki, Jun; Ogiya, Daisuke; Suzuki, Rikio; Toyosaki, Masako; Machida, Shinichiro; Omachi, Ken; Kawada, Hiroshi; Ogawa, Yoshiaki; Ando, Kiyoshi
• Is Part Of: Journal of infection and chemotherapy. Volume 28:Issue 9(2022)
• Page Start: 1279
• Page End: 1285
• Publication Date: 2022-09
• Subjects: Influenza virus -- Secondary pneumonia -- Hematopoietic stem cell transplantation; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2022.05.014
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: Introduction: Influenza virus infection (IVI) is frequent in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, and reports from several countries indicate high morbidity and mortality from progression to lower respiratory tract disease (LRTD). However, there have been no reports on IVI clinical characteristics, treatment outcomes, and risk factor for progression to LRTD among allo-HSCT recipients in Japan. Methods: We retrospectively reviewed the medical charts of allo-HSCT recipients who developed IVI between 2012 and 2019. Results: Forty-eight cases of IVI following allo-HSCT were identified at our institution. The median age was 42 years, and median time from allo-HSCT to IVI was 25 months. Thirty-seven patients (77.1%) were administered neuraminidase inhibitors (NAIs) as antiviral therapy within 48 h of symptom onset (early therapy), whereas 11 (22.9%) received NAI over 48 h after onset (delayed therapy). Subsequently, 12 patients (25.0%) developed LRTD after IVI. Multivariate analysis identified older age (hazard ratio [HR], 7.65; 95% confidence interval [CI], 2.22–26.3) and bronchiolitis obliterans (HR, 5.74; 95% CI, 1.57–21.0) as independent risk factors for progression to LRTD. Moreover, land-mark analysis showed that early therapy prevented progression to LRTD (11.8% vs. 45.5%, P = 0.013). The IVI-related mortality rate was 2.1%. Conclusions: Early NAI treatment is recommended for reducing the risk of LRTD progression due to IVI in allo-HSTC recipients, particularly for older patients and those with bronchiolitis obliterans.